Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria

Inclusion Criteria: * Patients with a pancreatic neuroendocrine tumor with a Ki67 index \<20%, who accept to participate and sign the consent form. In case of death patients, waiver of consent has been considered. * Patients who, according daily clinical practice, have been treated with sunitinib between February 2012 to end of inclusion period, with a follow up of at least 6 months. * Patients with a baseline imaging study (TC with arterial phase) and, at least, a 6-months follow-up evaluation. Patients with progression or exitus before the first imaging evaluation will not be included. Exclusion Criteria: * Patients with a follow-up of \<6months because of any other cause beyond progression of disease or exitus. * Patients without a baseline radiological evaluation or at 3/6 months. * Patients who do not accept to participate in the study. * Patients with anti-angiogenic treatment within 3 months prior to the start of sunitinib treatment. * Patients treated with sunitinib plus any other anti-proliferative agent beyond ASS.